Low-dose radiation and immunotherapy for resistant solid tumors
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a combination of low-dose radiation to the intestines and immunotherapy for people whose cancer has stopped responding to standard treatments including immunotherapy. It may offer a new option when other therapies have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- Your cancer has spread (metastatic) and has gotten worse after immunotherapy or similar treatment.
- You have at least one tumor that can be measured on scans.
- You are well enough to be up and about at least half the day (ECOG 0-2).
- You have not had radiation to your belly or pelvis in the last 6 months.
- You are not pregnant or breastfeeding, and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of low-dose radiation and immunotherapy can shrink advanced esophageal cancer enough to make it removable by surgery. It is for people whose cancer is considered borderline resectable or unresectable due to its location or spread.
This trial tests whether low-dose radiation can help people with advanced esophageal cancer that has stopped responding to standard chemotherapy plus immunotherapy. It aims to see if adding radiation can shrink tumors or slow the disease.
This trial tests a new type of radiation combined with immunotherapy for people with advanced solid tumors that are no longer responding to standard treatments or cannot tolerate them. The goal is to see if this combination can help control the disease.
This trial tests a low dose of radiation to the chest followed by a combination of an immunotherapy drug (adebrelimab) and chemotherapy for extensive-stage small cell lung cancer. Afterward, you would continue taking adebrelimab alone as maintenance therapy.
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
This trial tests a shorter course of radiation that avoids draining lymph nodes, followed by an immunotherapy drug (PD-1 inhibitor), for people with stage II or III rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink tumors while keeping lymph nodes intact.
Hear when a new Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.